SEC Form 4 · accession 0001737329-26-000010
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Iannone
Officer — EVP, Global Head of R&D & CMO
Period of report
Jun 30, 2026
Accepted (ET)
Jul 2, 2026 · 6:16 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Jun 30, 2026 | F | 3,764 | $237.72 | D | 85,107 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.